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Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by the selective death of lower motor neu-
rons in the brain stem and spinal cord. SMA is caused by mutations in the survival motor neuron 1 gene (SMN1), leading to the reduced expres-
sion of the full-length SMN protein. microRNAs (miRNAs) are small RNAs that regulate post-transcriptional gene expression. Recent findings
have suggested an important role for miRNAs in the pathogenesis of motor neuron diseases, including SMA. Motor neuron-specific miRNA dys-
regulation in SMA might be implicated in their selective vulnerability. In this study, we discuss recent findings regarding the consequences of
SMN defects on miRNAs and their target mRNAs in motor neurons. Taken together, these data suggest that cell-specific changes in miRNAs
are not only involved in the SMA motor neuron phenotype but can also be used as biomarkers and therapeutic targets.
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Introduction
Spinal muscular atrophy (SMA) is a severe neurodegenerative disease
with autosomal recessive transmission [1, 2]. SMA represents the
first genetic cause identified for infant mortality with an incidence of
approximately one in 11,000 live births [3]. The progressive degener-
ation of lower motor neurons located in the brain stem and spinal
cord leads to muscular weakness and, at later stages, to complete
paralysis [1, 2].
SMA is determined by mutations (predominantly homozygous
deletions) in the survival motor neuron 1 gene (SMN1, MIM#600354)
which encodes the full-length form of the SMN protein [4]. The SMN1
paralogous gene, SMN2, predominantly encodes a truncated and
unstable isoform through alternative splicing of exon 7. Only 10% of
the transcript encodes a full-length protein that can partially balance
the SMN1 absence. The number of copies of SMN2 in the patient’s
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genome largely determines the severity of the clinical presentation,
spanning from SMA type I, the early onset and most severe form that
is generally associated with two SMN2 copies, to the less severe
SMN II-IV forms, in which patients usually harbour multiple SMN2
copies [2]. The role of the SMN protein in SMA pathogenesis and its
function remain under study. This protein is ubiquitously expressed
in both the cytoplasm and the nucleus, but determines a selective vul-
nerability prevalently in motor neurons through mechanisms that are
still not completely understood [5]. SMN contributes to the biogene-
sis of snRNPs, the major components of mRNA splicing [6]. There-
fore, loss of SMN protein determines aberrant splicing and
widespread transcriptional changes, as demonstrated in different
SMA models, to which motor neurons can be particularly susceptible
[7–9]. It has also been suggested that a specific essential motor neu-
ron gene(s) is aberrantly altered, causing motor neuron loss [5]. Fur-
thermore, SMN plays an important role in neurite function, as it
regulates trafficking of RNA-binding proteins and the translation of
target mRNAs at these sites [10,11]. In fact, in vitro loss of SMN
leads to significant defects, not only in motor neuron survival but also
in neurite extension [12,13].
In December 2016, Nusinersen (SPINRAZATM), an antisense
oligonucleotide that modulates SMN2 splicing, received approval as a
therapy for all SMA types, becoming the first commercially available
drug for this disease [14]. Additional studies using different experi-
mental therapies, including gene therapy and small molecules that
modulate SMN2 splicing, have shown promising results in the
pre-clinical and early clinical trial stages. In this rapidly changing envi-
ronment, the definition of biomarkers to predict and follow disease
progression has become increasingly crucial.
With all this in mind, a mechanism that seems to be implicated in
the selective motor neuron vulnerability observed in SMA models is
the alteration of the expression of motor neuron-specific microRNAs
(miRNAs). In fact, the SMN protein is likely involved in miRNA bio-
genesis [15], which could also explain the numerous pathways that
are affected by SMN loss, as one miRNA can contemporaneously
control multiple genes.
miRNAs are small non-coding RNAs that are approximately 22
nucleotides in length. They regulate gene expression at the post-tran-
scriptional level; in particular, they bind specific sequences in the 30
UTR of target genes, inducing subsequent translational repression
and/or decay of target mRNAs (Fig. 1). As mentioned above, miRNAs
are able to regulate more than one target simultaneously and may
function in whole networks of genes modifying protein expression
[16].
Rationale for studying miRNAs in SMA
Numerous studies have suggested the importance of miRNAs in SMA
disease.
As mentioned above, SMN has a fundamental role in RNA pro-
cessing. In fact, SMN binds directly to proteins relevant for miRNA
generation and functionality, specifically fragile X mental retardation
protein (FMRP), KH-type splicing regulatory protein (KSRP) and
fused in sarcoma/translocated in liposarcoma (FUS/TLS), which is
one of the most frequent genetic causes of juvenile amyotrophic lat-
eral sclerosis (ALS) [17–19].
In spinal motor neurons, miRNAs are essential for the develop-
ment, differentiation, acquisition and maintenance of identity, axonal
growth, cytoskeletal structure, synapse formation and overall activity
[20–25]. The first observation suggesting the relevance of miRNA
regulation in motor neurons and their relationship with SMA was
made in transgenic mice harbouring a loss of Dicer function [26].
These studies demonstrated that a lack of Dicer within motor neuron
progenitors causes abnormal motor neuron development in the lateral
motor column; in adult mice, it leads to progressive motor neurode-
generation resembling SMA [26, 27]. These studies confirmed that
miRNAs are key elements for complete motor neuron function and
survival.
Because of these essential roles, it is not unexpected that dysreg-
ulation of RNA processing and miRNA expression are emerging as
mechanisms involved in motor neuron diseases [28, 29]. Many miR-
NAs are highly expressed in the central nervous system (CNS) and
participate in neuronal development and differentiation. Moreover,
miRNA function is indispensable for long-term survival of spinal
motor neurons in vivo.
Recently, it has been demonstrated that in ALS, the most com-
mon adult-onset motor neuron disease, aberrant miRNA expression
contributes to the disease pathophysiology and may represent a tar-
get for pharmacological intervention [28].
Increasing evidence also suggests that specific miRNAs can
determine the selective vulnerability of motor neurons also in SMA
[28, 29].
Here, we present and discuss several of these specific miRNAs
involved in SMA pathogenesis and their role as potential biomarkers
and therapeutic targets (Table 1).
miRNA-9 (miR-9)
miR-9 is one of the most abundant miRNAs in the CNS, with essential
functions as a regulator of neuronal function, generation and differen-
tiation. In particular, miRNA-9 has different functions during different
stages of development. Overall, miR-9 is pivotal in both spinal motor
neuron differentiation and correct positioning. During early stages of
development, as demonstrated in chicken embryos, miR-9 up-regula-
tion influences the differentiation of neural progenitor cells into spinal
motor neurons through inhibition of the transcription factor onecut1
(OC1) [21]. In later stages of development, miR-9 not only promotes
differentiation but also regulates the acquisition of the identity of a
subset of motor neuronal pools into the medial motor neuron column
through the inhibition of the Forkhead Box P1 transcription factor
(FoxP1) [22]. After differentiation, miR-9 has also been demonstrated
to regulate axonal development in mammals through the inhibition of
microtubule-associated protein 1B (MAP1B) [30]. Finally, later in life
miR-9 regulates motor neuron regeneration. In fact, miR-9 expres-
sion is reduced in the early phases of nerve injury in order to initiate
cell regeneration, while it is overexpressed in the later stages to
reduce the expression of pro-apoptotic genes. This pattern of expres-
sion is directly opposite to that of zinc finger CCCH-type containing
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12A (MCPIP1) – a pro-apoptotic gene [31]. All these findings con-
tribute to our understanding that regulation of miR-9 varies during
different stages of motor neuron life, suggesting a complex dynamic
phenomenon.
The first evidence suggesting the importance of miRNA dysregu-
lation, and specifically of miR-9, in SMA came from a study by Horn-
stein group that was published in 2010. In that study, conditional
ablation in spinal motor neurons in rodent models of Dicer1, a protein
that is fundamental for miRNA processing and maturation, altered
miRNA biogenesis and led to an SMA-like phenotype [26]. Dicer1 was
specifically knocked out by crossing a mouse with a Dicer1 condi-
tional allele with an animal harbouring a Cre-recombinase transgene
under a cholinergic-specific promoter. This allowed expression of the
transgene only in post-mitotic somatic motor neurons (at post-natal
day 7) and not during the development of these transgenic mice.
These animal models, which do not properly metabolize miRNA,
showed a neuromuscular phenotype and neuropathological features
that resemble those of SMA, including a loss of motor neurons, dam-
age of the ventral horns of the spinal cord, alteration of the structure
of the end plate, and atrophy and denervation of myofibres. The first
modifications in animal function were detected at 2 months of age. At
4 months, both electromyography (EMG) and histopathological anal-
ysis demonstrated motor neuron cell loss. Interestingly, the neurofila-
ment heavy subunit (NEFH), which is involved in the degeneration of
motor neurons in other motor neuron diseases such as ALS, was
overexpressed in the miRNA-deficient motor neurons, supporting its
Fig. 1miRNA transcription and mechanism of action. The transcription of primary microRNA (pri-miRNA) from miRNA gene is operated by RNA
polymerase II (Pol II). Pri-miRNA is then processed by Drosha (an RNase III enzyme) and its cofactor, Pasha, into 60- to 110-nucleotide pre-miRNA
hairpins in the nucleus. The pri-miRNA is then exported to the cytoplasm by exportin-5 via nuclear pore. In the cytoplasm, pri-miRNA is cleaved by
the RNase activity of Dicer into a transient, 22-nucleotide miRNA/miRNA* duplex intermediate. The duplex loads onto AGO2, an endonucleolytic
component of the miRISC, in the RISC complex (RNA-induced silencing complex) and separates. miRISC guides the antisense strand of the miRNA
in order to complement it with the target messenger RNA (mRNA) sequence, forming a double-stranded helix. mRNAs that bind with perfect com-
plementarity encounter endonucleolytic cleavage. On the other hand, when there is a partial complementarity, miRNA are subject to translational
repression, probably due to the formation of a bulge sequence in the middle of the helix that impedes the cleavage process.
ª 2017 The Authors.
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key role in determining the development of the SMA phenotype.
Intriguingly, this subunit is a target of miR-9, one of the most abun-
dant miRNAs in the CNS, and a key regulator of axonal extension and
branching in neurons [30]. The primary hypothesis for this observa-
tion is that the down-regulated miR-9 can no longer control the
expression of the NEFH, resulting in its up-regulation. These data sup-
port the relevance of miRNAs in motor neuron disease and confirm
the importance of miR-9 in regulating adult neuron survival. The path-
way regulated by Dicer–miRNA is fundamental for both the CNS and
peripheral nerve regeneration and axonal regrowth in vivo and in vitro
[31], as demonstrated by the effects of Dicer deletion in the murine
sciatic nerve [31]. In the same work from the Hornstein group [26],
the researchers also profiled the miRNA expression levels in an
in vitro model represented by motor neurons derived from embryonic
stem cells (ES) carrying a SMN1 mutant allele (SMN1mut). They used
murine SMA ES cells from a transgenic mouse that also expressed a
GFP reporter under the motor neuron-specific promoter HB9 (Tg
(Hlxb9-GFP)1Tmj Tg(SMN2)89Ahmb Smn1tm1Msd/J); thus, they
could monitor the correct differentiation of ES into motor neurons.
The researchers analysed the RNA extracted from these SMN1mut
motor neurons, purified with FACS according to the Hb9-GFP expres-
sion, and compared these RNA profiles with those obtained from
wild-type (WT) motor neurons. The authors demonstrated through a
quantitative PCR analysis that several specific miRNAs are signifi-
cantly reduced in SMN1mut motor neurons. In particular, the expres-
sion levels of miR-9 and miR-9* (two miRNA species processed from
the same hairpin) were reduced up to 15-fold. miR-9 is relevant to
motor neuron pathology, as noted above and as demonstrated by the
fact that it has neuron-specific expression and that it is down-regu-
lated in SMN1-deficient motor neurons. The mechanisms through
which miR-9 acts downstream of SMN1 and through which a specific
subset of SMA phenotypes is regulated by miR-9 should be further
investigated.
Wang et al. [32] proposed a different effect of SMN defects on
miR-9 expression. The authors down-regulated SMN expression
using gene-specific inducible short hairpin RNA interference (shRNAi)
in the motor neuron-like cell line NSC34 and in human skin fibroblast
cells. In these experiments, they observed that miR-9 levels showed a
time-dependent increase when cellular SMN protein levels were
diminished. In a complementary manner, cellular miR-9 levels
decreased over time after SMN overexpression in HeLa cells. They
also analysed the spinal cords of SMA mice and human primary skin
fibroblasts isolated from patients with different degrees of SMA dis-
ease severity. In these cellular models, miR-9 levels were increased
proportionally to the reduction in SMN. These data suggest a possible
role for miR-9 expression in certain cells as a prognostic marker, as
its expression appears to be regulated by the SMN protein and
directly correlates with the severity of SMA phenotype.
Catapano et al. [33], in line with the previous work of Haramati
et al. [26], demonstrated a significant down-regulation of miR-9 in
the spinal cord of SMA I mice compared with controls. By contrast,
they observed a greater than threefold increase in miR-9 in skeletal
muscle. Systemic treatment with morpholino oligonucleotides, which
modulated SMN2 splicing to allow production of a large quantity of
full-length protein, normalized miR-9 levels in skeletal muscle but not
in the spinal cord, further supporting miR-9’s potential utility as a bio-
marker. Higher levels of miR-9 were also detected in the serum of
SMA mice, and were reduced by morpholino treatment that up-regu-
lated SMN; these miRNA level changes occurred much earlier than
the changes in level in the spinal cord and skeletal muscle. miR-9
levels were also shown to be increased in the serum of SMA type II
and, to a lesser extent, in type III patients, who showed levels that
were intermediate between SMA type II patients and healthy controls.
Overall, the studies concerning miRNA-9 expression in SMA sug-
gest that miR-9 levels are significantly altered by the reduction of
the SMN full-length protein. miR-9 expression can be down- or
up-regulated depending on the SMA cells or tissues; it is likely down-
regulated in the CNS/motor neurons and up-regulated in other non-
neuronal cells and in the blood. However, knockdown of SMN in a
motor neuronal cell line resulted in miR-9 up-regulation [28], and
miR-9 expression is increased in the ALS SOD1G93A mouse spinal
cord [34]. These observations highlight the difficulties in generalizing
a conclusive profile of miR-9 expression in diseased motor neurons.
However, in a defined SMA pathological model, the miR-9 pattern of
expression is restored to the wild-type ‘normality’ by the up-regula-
tion of SMN expression, indicating its potential utility as a biomarker.
miR-206
Muscle involvement in SMA patients is related not only to skeletal
muscle denervation secondary to spinal motor neuron defects but
also to disruption of the myogenic program determined by SMN defi-
ciency [35, 36]. miR-206 is a miRNA that is primarily expressed in
muscle. It regulates the creation of myofibres and differentiation of
satellite cells [37]. Although miR-206 has been reported mainly to be
a skeletal muscle-specific miRNA, its expression has also been
detected in spinal motor neurons [38] where it has a role in the pro-
cess of regeneration of neuromuscular synapses [39, 40] after nerve
injury.
miR-206 regulates the processes of motor axonal growth and
muscle connection after acute nerve injury by influencing the expres-
sion of fibroblast growth factors (FGFs) and brain-derived neu-
rotrophic factor (BDNF), which are key elements of motor neuron
regeneration.
After acute nerve injury in mice, miR-206 is up-regulated and pro-
motes distal axon regrowth and muscle reinnervation through inhibi-
tion of the mRNA of histone deacetylase 4 (HDAC4), with consequent
increase of fibroblast growth factor binding protein (FGFBP1) [39].
This is secreted into the extracellular space, where it enhances FGF-7
action to elicit distal axon regrowth and muscle reinnervation [41].
Moreover, miR-206 may play a role as a negative regulator of BDNF
in skeletal muscle [42].
In a pathological context, such as in ALS, miR-206 has a neuro-
protective role and is involved in the regeneration of neuromuscular
junctions (NMJs) [39, 40]. In fact, miR-206 silencing in an ALS
mouse model accelerated disease progression [39]. In mouse models
of both muscular dystrophy and ALS, the miR-206 serum level is
increased in a possible compensatory manner [43]. A significantly
increased expression of miR-206 has been described in both the
ª 2017 The Authors.
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skeletal muscle and serum samples of ALS patients [44], supporting
its relevance as a possible biomarker for this disease, even though
further studies in larger cohorts remain necessary. While skeletal
muscle expression of miR-206 can exert a positive role, the serum
expression may be more likely related to the rate of clinical worsening
[44].
In SMA models, interestingly, the increase in miR-206 levels in
muscle delays neurodegeneration, despite not being able to com-
pletely rescue the integrity of motor neurons [45].
The authors of this study used the SMND7 mouse model to anal-
yse the correlation between miRNA-206 levels and NMJ architecture.
They demonstrated that the quadriceps, a muscle affected earlier in
this SMA model, shows a morphological pattern characterized by an
increase in atrophic fibres, a fibre type disproportion with a reduction
of type II fibres, and an accumulation of neurofilaments in the pre-
synaptic terminal of the NMJs. Furthermore, molecular investigation
showed that miRNA-206 also has an effect in regulating the HDAC4-
FGFBP1 pathway. In fact, as mentioned above for wild-type rodents,
miRNA-206 up-regulation determines the HDAC4 protein reduction
and consequent increase in FGFBP1 mRNA. This pathway has a neu-
roprotective effect and increases re-innervation of muscle endplates.
Overall, miR-206 may play a significant protective role in NMJs and
muscle and could represent a possible as yet unexplored therapeutic
target for SMA.
Treatment with oligonucleotides to increase SMN does not sig-
nificantly modify miRNA-206 levels in SMA I mice, either in the
spinal cord or in skeletal muscle, but does normalize its serum
levels [33].
It is intriguing that miRNA-206 is commonly dysregulated in both
SMA and ALS. In both of these disorders, miR-206 has been shown
to be able to partially delay the neurodegeneration process. miRNA
206 is capable of modulating the expression of several target genes
that could represent several common molecular pathways underlying
both ALS and SMA, thus representing potential therapeutic targets for
these diseases.
miR-132
Another miRNA highly represented in the CNS and with a putative role
in SMA disease is miR-132. Its role is mainly in the modulation of
neuronal dendritic outgrowth and synaptic function [46, 47]. miR-132
can delay neurite outgrowth in vitro and might interfere with radial
neuronal migration in the embryonic mouse neocortex in vivo [48].
miR-132 can be involved in the neovascularization process [49], in
particular in the vascular defects that have been observed in the
skeletal muscles and spinal cords of SMA models [50, 51]. Catapano
et al. [33] showed a reduction of miR-132 levels in the spinal cord of
SMA I mice, which was reversible with morpholino therapy. miR-132
levels in muscle were normal, while serum levels were elevated; these
normalized after oligonucleotide therapy. miR-132 expression is also
up-regulated in type II SMA patient sera, whereas the level in SMA III
patient sera was intermediate with respect to SMA II and healthy con-
trol sera. This pattern of tissue gene expression resembles that of
miR-9.
miR-183
Studies of miRNA expression demonstrate a different miRNA profile
in primary SMA cortical neurons with respect to control tissues [52].
Both animal and cellular models of SMA show an increased miR-183
level in fibroblasts, motor neurons and cortical neurons [52].
Specifically, researchers have found high levels of miR-183 in
neurites of SMN-deficient neurons and demonstrated how miR-183
up-regulation is able to suppress axonal growth [52]. Importantly,
both the altered expression and the altered distribution seen with
increasing concentrations in neurites might influence this process.
Moreover, it has been demonstrated that the translation of mecha-
nistic target of rapamycin (mTOR) is regulated by miR-183 through
its direct binding to the 30 UTR [50]. mTOR is a serine/threonine
kinase that forms two different complexes: mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). These complexes have
been demonstrated to regulate axon regeneration [53], cellular
cytoskeleton stability and mitochondrial biogenesis/degradation [54].
In SMN-deficient neurons, the local axonal translation of mTOR
appears to be reduced. In vivo experiments have demonstrated the
possibility of restoring it by inhibiting miR-183. This inhibition also
has functional consequences, as demonstrated by the fact that inhibi-
tion of miR-183 in the spinal cord in a SMA mouse model resulted in
an increase in median survival as well as motor function improvement
[52]. These data imply that miR-183, the mTOR pathway and the tight
regulation of the miR-183/mTOR balance may represent crucial
molecular mechanisms involved in SMA pathology. The role of basal
miR-183 expression in the regulation of motor neuron function and
survival remains to be determined. However, several studies have
demonstrated that even if increased expression of miR-183 has a
negative effect on motor neurons, basal expression levels and tran-
sient increases in miR-183 might be positive for motor neuron func-
tion. These observations highlight the need for further study
regarding the use of miR-138 as a therapeutic target, as this will
require precise modulation of its levels.
miR-335-5p
Recently, it has been demonstrated that miR-335-5p, which is known
to be able to control differentiation and self-renewal of mouse ES
[55], is also involved in SMA pathology. In fact, SMNΔ7 SMA and
wild-type (WT) neural progenitor cells derived from E13.5 mice spinal
cords have different expression levels of miR-335-5p. Furthermore, it
appears that miR-335-5p may also be associated with the increased
proliferation found in SMA cells [56].
Luchetti and his group [56] described for the first time the charac-
teristics of neural stem cells (NCSs) derived from the spinal cords of
a severe SMND7 SMA mouse model, comparing them to WT-derived
NSCs. While several characteristics remained the same, such as the
ability to form neurospheres and the expression of specific regional
and self-renewal markers, SMND7 NSCs had an altered cell cycle dis-
tribution as well as an increased proliferation rate compared to WT-
NSCs. These differences in proliferation may be observed because in
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SMND7 NSCs, the expression of certain miRNAs, such as miR-100-
5p and miR-335-5p, is reduced, further highlighting the potential role
of miRNAs in SMA pathology [56].
In the past decade, there has been growing interest in utilizing
induced pluripotent stem cells (iPSCs) as an in vitro model for genetic
disorders, because they offer the important possibility of studying
genetic diseases directly in human cells that are not accessible in live
patients, such as motor neurons.
In vitro models of SMA using human iPSCs have already been
described [57]. Specifically, we and other groups have demonstrated
that motor neurons derived from iPSCs from type I SMA patients
show low levels of the SMN protein, undergoing selective death over
time [8, 58, 59].
In a recent study, Murdocca et al. [60] analysed the molecular
and phenotypic features of SMA human iPSCs, specifically the gene
expression and cell cycle proliferation of SMA and WT iPSCs in the
process of differentiating into early motor neurons. Their study con-
firmed a reduced level of miR-335-5p in SMA cells, which could be
associated with a low expression of early motor neuron markers [60].
Using quantitative reverse transcription PCR (qRT-PCR), it was
possible to demonstrate that while the expression of miR-335-5p is
almost equivalent between SMA and WT iPSCs, it begins to signifi-
cantly differ at both 14 and 22 days of differentiation. After 14 days,
miR-335-5p appears to be down-regulated more than twofold in SMA
versus WT cells, and after 22 days, the difference is even more pro-
nounced. This evidence suggests that miR-335-5p may be involved in
the process of differentiation of iPSCs towards early motor neurons
[60].
These new results regarding the correlation between down-regu-
lation of miR-335-5p in differentiating cells and SMA are important,
as they suggest an involvement of this specific miRNA in SMA pathol-
ogy specifically in cells that are differentiating towards motor neu-
rons.
As previously reported, at the iPSC stage there is no difference in
miR-335-5p expression, while the difference becomes more signifi-
cant after 2 and 3 weeks of differentiation. This evidence deserves
further in-depth analysis in order to better understand how miR-335-
5p down-regulation is involved in SMA precursor differentiation and,
most importantly, its possible correlation with SMA phenotype.
miR-431
The Sahin group [61] demonstrated that SMN knockdown alters
miRNA expression with a pattern that is specific for each type of
cell. The aim of their study was to define the consequences of SMN
loss in miRNAs and their target mRNAs in spinal motor neurons.
RNAseq was used to analyse both miRNA and mRNA expression in
primary spinal cord motor neuron cultures after acute SMN loss.
This in vitro model was created using wild-type embryonic rat spinal
motor neurons infected with lentiviral shRNA specific for down-regu-
lating SMN (shSMN). Both Western blot and qRT-PCR analyses were
used to evaluate SMN knockdown. After 6 days, these methods
demonstrated an 80% and 75% reduction, respectively, in SMN pro-
tein levels [61].
Through the integration of miRNA/mRNA profiles, it was possible
to detect a number of dysregulated miRNAs (n = 17) with increase in
several of their putative mRNA targets. The expression of miR-431
was very high, while a number of its putative target mRNAs were con-
siderably down-regulated in motor neurons with reduced SMN levels.
It has been previously described that miR-431 is expressed in the
brain as well as in the spinal cord during embryonic development
[62].
Interestingly, by studying iPSC-derived motor neurons of type I
SMA patients, it was possible to detect a marked increase in miR-
431. This change appears to be specific to motor neurons, because it
was not present in fibroblasts derived from type I SMA patients. By
measuring the primary miR-431 transcript level (pri-miR-431), which
was also increased, it was possible to establish that the mechanisms
underlying the miR-431 increase may include its augmented primary
transcription. Moreover, Wertz et al. discovered that miR-431 was
also involved in the regulation of neuronal neurite outgrowth (Fig. 2).
Therefore, by inhibiting the overexpression of miR-431 in SMN-defi-
cient motor neurons, it is possible to rescue the motor neuron neurite
length phenotype. The authors also identified chondrolectin (Chodl), a
type 1 transmembrane protein and member of the c-type lectin
domain-containing family [61], as a direct target of miR-431. Chodl is
fundamentally important because it regulates the outgrowth of motor
neurons axons. This observation suggests that the lack of axonal out-
growth in SMA motor neurons may be due to a down-regulation of
Chodl caused by an increase of miR-431 [61].
miR-375
miR-375 has two important functions: it contributes to the promotion
of the acquisition of a motor neuron phenotype and protects neurons
from apoptosis after DNA damage.
During development, miR-124 promotes neurogenesis through
RE1-silencing transcription factor (REST) silencing [63]. REST is a
transcription factor (TF) that plays a key role in regulating the balance
between self-renewal and neuronal differentiation, suppressing neu-
ronal genes in non-neuronal tissues. Moreover, it plays a crucial role
in various stages of neuronal development, such as the differentiation
of embryonic stem cells (ESCs) into neural stem cells (NCSs), and
further differentiation of NCS into neurons. Bhinge et al. investigated
which miRNAs were regulated by REST using Rest-null mouse ESC,
in which normally suppressed miRNAs should be highly activated
[62]. Among various miRNAs that were differentially expressed in
response to Rest knockout, Bhinge’s group focused on miR-375,
which was not only up-regulated after Rest knockout, characterizing it
as one of Rest’s direct targets, but was also highly expressed during
neuronal differentiation of wild-type ESC, thus likely being implicated
in neurogenesis [62]. Using an in vitro model of spinal motor neuron
development, Bhinge et al. discovered that miR-375 is highly acti-
vated during spinal motor neurogenesis and that its expression is
specific to MNs, indicating an essential role for miR-375 in motor
neuron development.
miR-375 promotes motor neuron differentiation through silencing
PAX6 and cyclin D2 (CCND2) transcript expression, both of which are
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
761
J. Cell. Mol. Med. Vol 22, No 2, 2018
direct targets of miR-375. This silencing enhances motor neuron dif-
ferentiation [64]; PAX6 is also important for the generation of neural
progenitor cells and for the correct balance between self-renewal, pat-
terning and differentiation in the developing spinal cord.
The timing of REST silencing is fundamental. In fact, in order to
allow the formation of post-mitotic spinal motor neurons, miR-124
must silence REST activity and miR-375 must suppress PAX6 at
specific time-points [63, 64].
The second major function of miR-375, the protection from apop-
tosis, is mediated by reduction of tumour suppressor p53 protein
levels [64]. According to its pro-apoptotic function, p53 levels remain
low in mature neurons. After DNA damage, developing motor neurons
show an increase in p53 expression, which leads to programmed cell
death [65]. It has been demonstrated that overexpression of miR-375
can prevent cell death after DNA damage [64].
p53-mediated neuronal apoptosis has been described in various
neurodegenerative disorders, including ALS and SMA [66, 67].
Bhinge et al. observed that in SMA motor neurons, p53 levels
were remarkably high while miR-375 levels were extremely low
[64]. This observation is also consistent with the fact that SMA
MNs are much more susceptible to DNA damage compared to
healthy MNs. Exogenous expression of miR-375 was able to rescue
SMA motor neurons from cisplatin-induced apoptosis, strengthen-
ing the hypothesis that miR-375 exerts a protective effect by
inhibiting p53 and has a general protective role in spinal MNs [65].
The identification of these new regulatory mechanisms involved in
SMA pathogenesis may lead to new potential therapeutic
approaches for SMA.
miR-2
The possible role of miR-2 in SMA pathogenesis has recently been
demonstrated.
Fig. 2 Increased primary transcription, as testified by high levels of pri-miR-431, leads to high miR-431 levels. There is a set of miR-431 genes that
are down-regulated in SMN knockdown, among which chondrolectin (Chodl), a C-type lectin, is a key regulator of motor neuron outgrowth. miR-
431 binds to the Chodl 30UTR site inducing its translational repression and decay. Low Chodl levels translate into impaired axonal development and
outgrowth, a core feature of SMA. Interestingly, in SMN knockdown miR-431 levels are normal in fibroblasts and cortical neurons, making its
increased expression a specific feature of motor neurons.
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In mice, miR-2 acts as a negative regulator of m2R (a muscarinic
acetylcholine receptor important for neurons) and as an inhibitor of
cholinergic MN synaptic release [68]. miR-2 is a specific target of
Gemin3, which is a protein that interacts with SMN and participates in
microRNA processing. In particular, Gemin3 is an RNA helicase that
correlates both with SMN and RNA-induced silencing complex com-
ponents and may also play a role in spliceosome assembly, mRNA
transport and miRNA function in general [68].
Recently, Patrick O’Hearn et al., using a C. elegans model,
reported that the reduction of SMN levels can cause neuromuscular
junction (NMJ) dysfunction in motor neurons and suggested that dys-
regulation of neurotransmission may represent another pathological
mechanism in SMA [69].
According to their model, loss of the C. elegans SMN orthologue
SMN-1 causes mir-2 and consequently GAR-2 (C. elegans m2R
orthologue), miR-2 dysregulation and NMJ defects. Increasing in C.
elegans the Gemin3 orthologue MEL-46 modifies miR-2 expression
and ameliorates NMJ defects.
GAR-2 and m2R are functionally conserved, as activation of these
pre-synaptic receptors by acetylcholine in different species results in
hyperpolarization and decreased NMJ acetylcholine release across
species, and several treatments that block m2R are currently available
to treat other conditions.
In a SMA mouse model, m2R levels showed an increase of 50%
compared to controls, and pharmacological inhibition of m2R by
methoctramine was able to rescue MN phenotype and to overcome
MN axon outgrowth defects.
Collectively, these results suggest that m2R up-regulation in SMA
at early stages may contribute to MN dysfunction, resulting in overac-
tive neurotransmission and that therapies that target miR-2 expres-
sion can modify disease evolution.
miR-146
The precise mechanisms that lead to selective motor neuron loss
in SMA are currently under investigation, but it is well known that
extrinsic influences, such as those arising from astrocytes, may
also contribute to SMA pathogenesis. Among the different mecha-
nisms suggested, altered expression of miRNAs in astrocytes has
recently been highlighted. Sison et al. specifically investigated
miRNA expression and secretory profiles in SMA astrocyte models,
and they demonstrated that miR-146a was the only miRNA that
was up-regulated [70]. This miRNA is not overexpressed in motor
neurons and appears to have a role in the regulation of the
immune system response to interleukins, TNF-a and glial activation
[71]. miR-146 exerts its action by down-regulating glial-derived
neurotrophic factor (GDNF), which is a potent survival factor for a
number of neuronal subtypes [72], and by acting on NOTCH sig-
nalling. miR-146 levels are influenced both directly and indirectly
by SMN1 levels. SMN re-expression decreases miR-146a levels
nearly to control levels, and the NFjB pathway is instead an indu-
cer of miR-146a. The pathogenic role of this miRNA is demon-
strated by the fact that treatment of iPSC-derived motor neurons
in vitro with synthetic miR-146a molecules can mimic SMA
pathogenesis and induce motor neuron loss. Moreover, miR-
146a inhibition rescues the SMA phenotype [70] Together, these
data indicate that altered astrocyte production of miR-146a may be
a contributing factor in astrocyte-mediated SMA pathology and that
miR-146a regulation, such as through regulation of NFjB sig-
nalling, could represent an additional therapeutic target for the
treatment of SMA.
How can miRNA alteration account for
selective motor neuron death in SMA?
The critical role of the SMN protein in miRNA biogenesis and process-
ing confirms the importance of miRNAs in SMA pathogenesis Overall,
miRNAs have multiple functions and appear to be fundamental for
neuronal survival. However, the expression of miRNA is highly vari-
able in different neuronal cells and in different stages of cell develop-
ment. In fact, each neuronal subtype is characterized by a specific
miRNA profile that changes over the course of the development,
maintenance and regeneration phases. Their highly specialized mor-
phology and function make motor neurons strictly dependent on pre-
cise miRNA functioning and regulation.
One of the main questions in the miRNA/SMA field is how to inter-
pret miRNA specificity for diseases, as miRNAs are involved in sev-
eral functions related to neuronal involvement. The link between
miRNA disruption and selective motor neuron death likely resides in
their targets.
For example, miR-9 alteration leads to reduced down-regulation
of heavy neurofilaments, a pathogenic process that specifically
involves motor neurons. In fact, neurofilament accumulation has
been supported by several studies as one of the more likely causes
of selective motor neuron degeneration. The neurons that are most
prominently affected by the accumulation of neurofilaments are the
largest neurons with the longest axons, which normally contain
abundant neurofilaments. Indeed, cytoskeletal abnormalities may
augment the susceptibility of neurons to other insults, for example
excitotoxicity, so that multiple elements culminate in the disease
[31].
The miR-183/mTOR pathway regulates local axonal translation
and axonal growth, which are fundamental in motor neurons. Inter-
estingly, miR-183 partially rescues the neuronal phenotype induced
by SMN loss, and can be an additional target besides the modulation
of the mTOR pathway.
Also miRNAs which are specifically altered in astrocytes, such as
mi-146, can influence motor neuron development due to their high
dependence on extrinsic influences.
Current knowledge confirms the importance of changes in miRNA
expression, especially in early disease stages in the miRNA–mRNA
regulatory network in the pathogenesis of SMA. Although several
pathways, targets and intersections have now been determined, a
more detailed understanding of the transcriptome networks in both
healthy and diseased motor neurons is fundamental to establishing
further understanding of the pathogenesis and mechanisms that lead
to selective motor neuron susceptibility.
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miRNA as biomarkers in SMA
Despite significant progress in the understanding of SMA pathogene-
sis, definition of the biomarkers for this disease is still lacking. With
promising therapies progressing through clinical development, there
is an urgent need for the definition of molecular biomarkers that could
be fundamental to performing patient classification, following disease
evolution and better defining the efficacy of therapeutic approaches
using minimally invasive procedures.
Overall, miRNAs hold an interesting diagnostic and prognostic
potential as non-invasive biomarkers for SMA. In fact, miRNAs are
relatively stable in accessible biofluids, such as blood and CSF, and
can be detected with accessible and feasible laboratory methods.
Moreover, multiple samples can be captured in order to follow dis-
ease evolution over time.
Among the miRNAs highlighted in this review, miR-9, miR-132,
miR-206, miR-183 and miR-375 could represent possible biomarkers
for SMA, while miR-183 and miR-375 may play additional roles in
contributing to the specificity of SMA determination, based on the
data presented above in each miRNA subchapter. The major critical
challenges remain the possible inconsistencies in the results due to
human subject variability and technical issues related to the relative
fragility of miRNAs. In general, one of the critical aspects is the speci-
ficity of this kind of biomarker.
The recruitment of large cohorts of patients could increase the
power of biomarker studies and promote the advancement of the
field.
miRNA as a therapeutic target in SMA
Over the last several years, given their specific ability as broad tran-
scriptomic regulators, miRNAs have been proposed as promising
therapeutic targets for neurodegenerative diseases, including motor
neuron disorders. Schematically, there are two possible approaches
to modulating miRNAs: (i) overexpressing them with miRNA mimics
or (ii) down-regulating them through antisense oligonucleotides (anti-
miRNAs) [73].
However, there are many issues that must be overcome and that
make it difficult to use miRNA for therapeutic purposes. One of these
challenges is the method of delivery: these molecules can be deliv-
ered either naked to the target tissues, at the price of being quickly
degraded or having limited cell penetration, with some modifications
(peptide), or with the use of delivery tools such as nanocapsules
[73]. The most effective route of delivery must also be determined:
intrathecal injection allows higher concentrations and more selective
action but is more invasive; therefore, systemic administration should
also be considered. Furthermore, it must be considered that miRNAs
often act through multiple pathways and that there is the risk that
they may influence transcription in off-target tissues, leading to the
possibility of significant side effects and adverse events. Finally, the
timing of miRNA regulation according to their cellular developmental
status must also be considered, as miRNA levels should be modu-
lated at the correct stage of development.
Among the miRNAs presented in this review, miR-9, miR-206,
miR-183 and miR-375 could potentially be explored as therapeutic
targets for SMA.
miR-9 represents one of the most interesting targets because it is
the one with the most relevance to motor neuron function. The vast
majority of experimental evidence suggests that miR-9 is generally
down-regulated in SMA spinal cords. Thus, one possible therapeutic
strategy could be its up-regulation via gene/molecular therapy. How-
ever, miR-9 is a key player in many processes within many cells. Its
expression is tightly regulated and can vary significantly between
each phase of motor neuron regeneration, being first up-regulated
and later down-regulated. Thus, artificially mimicking these complex
variations with pharmacological or gene therapy without inducing sig-
nificant off-target effects may be difficult. Indeed, the findings of
miR-9 down-regulation are not consistent in all data sets in the litera-
ture, and conflicting results have been observed depending on the
SMA model/cell type considered. In any case, the testing of miR-9 as
a therapeutic target warrants further investigation in pre-clinical SMA
models.
miR-206 may play a significant protective role in NMJs and mus-
cles and represents a potential unexplored therapeutic target for
SMA.
Regarding miR-183, its expression in the spinal cord of an SMA
mouse prolonged survival and improves motor function of Smn-
mutant mice [52]; therefore, miR-183 might also represent an inter-
esting target.
Finally, miR-375 can confer motor neuron protection by shielding
motor neurons, via inhibition of p53, from increased susceptibility to
DNA damage-induced apoptosis [65].
miRNA therapeutic strategies can also be used to directly up-reg-
ulate SMN levels.
It has been recently demonstrated in zebrafish that the expres-
sion of anti-smn1 miRNAs in motor neurons reproduced most of the
hallmarks observed previously in the ubiquitous knockdown model.
In addition, smn1 knockdown in zebrafish motor neurons is suffi-
cient to induce late-onset motor neuron degeneration [74]. Based on
this observation, it is possible to determine a strategy to block anti-
SMN1 miRNA with anti-miRNAs, with the goal of up-regulating SMN
levels.
The demonstration of the expression of anti-SMN1 or SMN2 miR-
NAs in mammalian motor neurons is the first step to further develop-
ing this idea.
Conclusions and perspectives
miRNA dysregulation likely has an important role in SMA pathogenesis
and in determining the selective vulnerability of motor neurons. In par-
ticular, miRNA activity seems to be fundamental for the survival and
function of post-mitotic spinal motor neurons. miRNA homeostasis
disruption in murine spinal motor neurons contributes to the appear-
ance of typical hallmarks of SMA. Different studies have shown altered
expression of specific miRNAs in SMA, and several of these experi-
ments have highlighted the same miRNAs in different SMA models.
The miRNAs related to neuronal function are those most frequently
764 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
identified as aberrantly expressed, even if the exact molecular mecha-
nisms in which they are involved are largely undefined. Further investi-
gations of this perspective will allow increased understanding of how
miRNAs intervene in SMA pathogenic mechanisms. The expression
profile of each miRNA can vary in different tissues, such as muscle,
serum and spinal cord, and can even reflect the severity of SMA, being
more altered in SMA I than SMA II and SMA III.
Therefore, miRNAs can be used not only as biomarkers of pathol-
ogy but also as markers of disease severity and progression, as well as
of response to effective experimental therapies in future clinical trials.
Furthermore, the therapeutic potential of miRNAs must be thoroughly
explored. Given that in vitro and in vivo experiments have demon-
strated the neuroprotective potential of certain miRNAs, this would be
an important topic to be assessed in subsequent studies for imple-
menting novel SMA therapies. For instance, miRNA can be modified by
RNA therapy, including antisense oligonucleotides, miRNA mimics and
antagomirs, and could represent a promising potential therapeutic tar-
get for SMA in association with SMN-targeted therapies.
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